Carotid endarterectomy (CEA) is a surgical procedure performed to reduce the risk of stroke in patients with significant carotid artery disease. This procedure does not apply to haemorrhagic strokes (bleeding in the brain), which make up the other 25% of strokes. The surgery to remove this narrowing in the carotid artery can help prevent a stroke. However, it cannot improve the outcome of a stroke that has already occurred. CEA is more effective than medical management in the prevention of stroke. However, this is true for certain groups of patients under defined circumstances.
In patients with symptomatic and severe disease of >70-99%, such as patients with symptoms of stroke, transient ischaemic attack (TIA or mini-stroke) or amaurosis fugax (transient blindness) due to carotid artery narrowing of >70-99%, CEA has significant benefit over medical management. The risk-benefit ratio favors surgery only if the perioperative morbidity and mortality is <6%.
Patients with asymptomatic disease and carotid artery stenosis of >60%, such as patients with carotid artery narrowing of >60% but who experience no symptoms, benefit substantially less from CEA. For any benefit at all, surgery must be performed at very low stroke rates, in the range of 2-3%.
In symptomatic severe carotid artery narrowing, several trials have shown CEA to be superior to medical management for the prevention of stroke. The North American Symptomatic Carotid Endarterectomy Trial (NASCET), published in 1991, showed a significant benefit for CEA in patients with severe carotid artery stenosis of >70% demonstrated on angiography. In the NASCET trial, CEA resulted in an absolute risk reduction of stroke by 17% at 2 years. This difference in outcome between medical therapy and surgery plus medical therapy represented a relative risk reduction of 65%. Thus, surgery was beneficial for persons with severe carotid artery narrowing and who had experienced a stroke or its warning signs. The European Carotid Surgery Trial (ECST), published in 1991, also demonstrated a similar benefit in such patients with severe carotid artery stenosis. It is important to realise that the perioperative stroke and death rate has to be <6% for CEA to be effective.
CEA has been shown to be beneficial in patients without symptoms but this benefit is less substantial. The Asymptomatic Carotid Atherosclerosis Study (ACAS), published in 1995, is the largest and most definitive randomised trial that evaluated the efficacy of surgery in patients with severe stenosis of >60% detected by ultrasound. The 5-year projected risk of stroke was reduced by surgery from 11% to 5.1%. While this is translated to a relative risk reduction of 53%, the absolute risk reduction at 2 years was only 1.5% (meaning that 67 patients would need to undergo surgery to prevent one non-disabling stroke). Furthermore, surgery did not protect against major stroke and death and the results were not significant when women were analysed as a discrete population. With a modest benefit of surgery in patients were severe stenosis and no symptoms, carotid endarterectomy is not routinely recommended. It should be only considered as a management option by surgeons with very low complication rates of <3% in the presence of other high risk factors (eg, stenosis of the opposite carotid artery, plaque ulceration etc). Medical management is a sensible alternative for most of such patients.
The surgery involves a skin incision is placed obliquely across the side of the neck. The branches of the artery and the carotid artery before and after the site of narrowing are clamped and an openning is then made over the area of narrowing. The plaques causing the narrowing are removed and the openning is repaired with very fine sutures.
The potential risks for this procedure are as listed: